Inovio Pharmaceuticals 過去の業績

過去基準チェック /06

Inovio Pharmaceuticalsの収益は年間平均-0.6%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間7.7% 9.5%割合で減少しています。

主要情報

-0.6%

収益成長率

17.2%

EPS成長率

Biotechs 業界の成長	11.5%
収益成長率	-9.5%
株主資本利益率	-153.5%
ネット・マージン	-55,491.1%
前回の決算情報	30 Sep 2024

Recent updates

収支内訳

Inovio Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

LSE:0A43 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
30 Sep 24	0	-113	40
30 Jun 24	1	-122	41
31 Mar 24	1	-125	45
31 Dec 23	1	-135	48
30 Sep 23	1	-165	37
30 Jun 23	10	-168	39
31 Mar 23	10	-241	73
31 Dec 22	10	-280	76
30 Sep 22	11	-332	90
30 Jun 22	2	-355	92
31 Mar 22	2	-328	56
31 Dec 21	2	-304	54
30 Sep 21	7	-221	48
30 Jun 21	6	-142	45
31 Mar 21	6	-188	44
31 Dec 20	7	-166	37
30 Sep 20	2	-180	37
30 Jun 20	3	-222	33
31 Mar 20	3	-123	28
31 Dec 19	4	-119	27
30 Sep 19	6	-115	24
30 Jun 19	7	-117	25
31 Mar 19	32	-94	27
31 Dec 18	30	-97	29
30 Sep 18	37	-86	32
30 Jun 18	37	-95	31
31 Mar 18	33	-97	30
31 Dec 17	42	-88	28
30 Sep 17	42	-93	27
30 Jun 17	52	-80	27
31 Mar 17	38	-89	26
31 Dec 16	35	-74	24
30 Sep 16	33	-65	22
30 Jun 16	44	-39	20
31 Mar 16	44	-27	19
31 Dec 15	41	-29	18
30 Sep 15	37	-19	17
30 Jun 15	15	-31	16
31 Mar 15	13	-36	16
31 Dec 14	10	-36	16
30 Sep 14	10	-44	16
30 Jun 14	17	-68	16
31 Mar 14	14	-68	15
31 Dec 13	13	-66	14

質の高い収益: 0A43は現在利益が出ていません。

利益率の向上: 0A43は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 0A43は利益が出ておらず、過去 5 年間で損失は年間0.6%の割合で増加しています。

成長の加速: 0A43の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 0A43は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: 0A43は現在利益が出ていないため、自己資本利益率 ( -153.49% ) はマイナスです。

Inovio Pharmaceuticals 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings released: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Second quarter 2024 earnings released: US$1.19 loss per share (vs US$1.61 loss in 2Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

New major risk - Share price stability

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

New minor risk - Profitability

Second quarter 2024 earnings released: US$1.19 loss per share (vs US$1.61 loss in 2Q 2023)

Inovio Pharmaceuticals, Inc. Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

INOVIO Appointsof Steven Egge as Chief Commercial Officer

New minor risk - Profitability

First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $35.937522 million.

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Full year 2023 earnings released: US$6.09 loss per share (vs US$14.07 loss in FY 2022)

Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.15 loss in 3Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.46 loss in 2Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Value Index

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.36 loss in 1Q 2022)

INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®)

Inovio Pharmaceuticals, Inc. Announces Strategic Reorganization and 11% Reduction of Full-Time Employees

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.29 loss in 3Q 2021)

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

Inovio Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.39 loss in 2Q 2021)

Inovio Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R) (cemiplimab) in Patients with Newly Diagnosed GBM

INOVIO Announces Board Changes

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.27 loss in 1Q 2021)

No longer forecast to breakeven

No longer forecast to breakeven

Inovio Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

High number of new directors

INOVIO Updates on Phase 3 Program for VGX-3100 for HPV-Associated Cervical High-Grade Squamous Intraepithelial Lesions

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.12 profit in 3Q 2020)

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

Forecast to breakeven in 2023

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vaccine Candidate, INO-4800

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.83 loss in 2Q 2020)

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine against Middle East Respiratory Syndrome, a Coronavirus Disease

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 3000 Growth Index

Forecast breakeven pushed back to 2024

Inovio's Pan-Covid-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.26 loss in 1Q 2020)

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

INOVIO Announces Positive Results from REVEAL 1, Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-Based HPV Immunotherapy for the Treatment of High-Grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Full year 2020 earnings released: US$1.07 loss per share (vs US$1.21 loss in FY 2019)

Revenue beats expectations

QIAGEN N.V. and Inovio Pharmaceuticals Announces an Extension of Their Partnership with A New Master Collaboration Agreement to Develop Liquid Biopsy-Based Companion Diagnostic Cervical Dysplasia

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

過去基準チェック /06